baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Voyager Therapeutics/ US92915B1061 /

6/4/2024 5:02:58 PM	Chg. -0.04	Volume	Bid5:14:00 PM	Ask5:14:00 PM	High	Low
8.60USD	-0.46%	1,308 Turnover: 11,307.21	8.48Bid Size: 100	8.57Ask Size: 100	8.74	8.46

GlobeNewswire 5/16 Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 f...

GlobeNewswire 5/13 Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results

GlobeNewswire 5/8 Voyager Therapeutics Presents Data for Second-Generation, TRACER™-Generated Capsids and CNS Gene The...

GlobeNewswire 5/7 DBV Technologies Reports First Quarter 2024 Financial Results and Business Update

GlobeNewswire 5/6 Voyager Therapeutics Announces First Quarter 2024 Conference Call and Webcast

GlobeNewswire 4/22 Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Th...

GlobeNewswire 4/16 Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration ...

GlobeNewswire 3/28 Inventiva announces the nomination of Andre Turenne as Director

GlobeNewswire 3/26 Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 3/13 Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer

GlobeNewswire 2/29 PRISM MarketView Highlights Work of Emerging Companies on Rare Disease Day

GlobeNewswire 2/28 Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

GlobeNewswire 2/26 Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich’s Atax...

GlobeNewswire 2/21 Voyager Therapeutics Announces Fourth Quarter 2023 Conference Call and Webcast

GlobeNewswire 2/20 Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for A...

GlobeNewswire 1/5 Voyager Therapeutics Announces Pricing of Public Offering

GlobeNewswire 1/4 Voyager Therapeutics Announces Proposed Public Offering

GlobeNewswire 1/3 Voyager Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire 1/2 Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Ad...

GlobeNewswire 12/6/2023 Voyager Therapeutics Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Scler...

GlobeNewswire 12/1/2023 Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator

GlobeNewswire 11/6/2023 Voyager Therapeutics Reports Third Quarter 2023 Financial and Operating Results

GlobeNewswire 10/30/2023 Voyager Therapeutics Announces Third Quarter 2023 Conference Call and Webcast

GlobeNewswire 9/25/2023 Voyager Therapeutics to Present at the Chardan Genetic Medicines Conference

GlobeNewswire 9/7/2023 Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Voyager Therapeutics/ US92915B1061 /

If you wish to receive reply to your feedback, please provide your email address.